Weiyun Ai

Weiyun Ai, MD, PhD, is a Professor at the University of California, San Francisco (UCSF) School of Medicine. She specializes in hematologic malignancies, focusing on Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, and cutaneous lymphomas, with extensive clinical trial involvement.

• Education: MD from Stanford University (2000), Residency at UCSF in Internal Medicine.

Her research spans targeted therapies for lymphomas, patient-derived xenograft models, and clinical trial design. Articles reflect expertise in antibody-drug conjugates, geriatric assessments, and genomic biomarkers for lymphoma subtypes. Key collaborations include NCCN guideline development for Hodgkin lymphoma and T-cell lymphomas.

Scientific contributions include:

• Loncastuximab tesirine trials (LOTIS-2) for DLBCL
• Evolution of NCCN guidelines for lymphoma
• Investigation of T-cell clone dynamics in mycosis fungoides
• Preclinical studies on CD70 targeting and PI3K/HDAC inhibition